Prostate cancer, disease characterized by uncontrolled growth of cells within the prostate gland. Prostate cancer is a frequently diagnosed cancer among males. Learn more about the causes, symptoms, and treatment of prostate cancer.
近期,来自澳大利亚的研究人员在《Prostate Cancer P D》上刊文,深入调查了中会危癌病变执意检测后的病变结果。 研究以外了26548名接纳AS监管的年长者,年龄 结果发现,在1731名患有GG 1疾病和PSA 10-20 ng/mL的年长者中会,382人(22.1%)存在不良病变,而在8367名GG 2和PSA PSA水平和活检层级组预测RP时不良病变...
RESULTS: Median values from data of men's ages, IPSS, QOL and PSA were 63 years, 11, 2, and 1.23 ng/ml, respectively. 9 of 200 patients (4.5%) were found to have prostate adenocarcinoma on biopsy. Most of the cancer cases showed a localized lesion. Prostate cancer was found more ...
Prostate cancer screening with DRE, TRUS, and PSA testing was offered to 2,400 randomly selected men 55-70 years old. Among 1,782 examined, 65 (3.6%) men with prostate cancer were diagnosed. The PSA results were correlated to the diagnosis, the men's age, and the prostate volume. Least...
PSA (KLK3) protein abundance was consistently significantly reduced in all fractions of urine from prostate cancer patients relative to men without a cancer diagnosis, despite being increased in serum and in tumor regions19(Fig.5c–e). Therefore, our data suggest that pathways associated with malig...
prostate cancer (cT3a, Gleason 4+3, PSA 21.6)Charles Richardson
Prostate cancer has come to share the oncological centrestage among male cancers. The availability of Serum Prostate Specific Antigen, PSA, as a marker has encouraged it's use to diagnose both cancer and cancer recurrence. Some clarity is required about its precise role in clinical practice. The...
PSA (prostate specific antigen):The PSA test is a blood test usually performed in addition to DRE and increases the likelihood of prostate cancer detection. The test measures the level of PSA, a substance produced only by the prostate, in the bloodstream. While PSA is specific to the prostate...
5.3. Treatment of Non-Metastatic Castration-Resistant Prostate Cancer The definition of castration resistance in addition to radiological progression includes an increase in PSA with the patient’s castrate testosterone level. Sometimes PSA progression occurs without visible metastases by conventional imaging ...
To manage a loss of libido with prostate cancer, you can: Ask your doctor about breaks with your hormone therapy treatment, or only restart treatment when your prostate-specific antigen (PSA) levels begin to rise Talk to your doctor about drug treatment for erection problems ...